Ocugen, Inc.

NasdaqCM:OCGN Stock Report

Market Cap: US$225.6m

Ocugen Management

Management criteria checks 2/4

Ocugen's CEO is Shankar Musunuri, appointed in Sep 2013, has a tenure of 11.25 years. total yearly compensation is $4.54M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth $1.45M. The average tenure of the management team and the board of directors is 1.8 years and 4.9 years respectively.

Key information

Shankar Musunuri

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage16.7%
CEO tenure11.3yrs
CEO ownership0.6%
Management average tenure1.8yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Sep 14

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Aug 23

CEO Compensation Analysis

How has Shankar Musunuri's remuneration changed compared to Ocugen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$51m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$5mUS$758k

-US$63m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$8mUS$715k

-US$87m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$8mUS$541k

-US$58m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$500k

-US$34m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$572kUS$420k

-US$20m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$431kUS$420k

-US$18m

Compensation vs Market: Shankar's total compensation ($USD4.54M) is above average for companies of similar size in the US market ($USD1.41M).

Compensation vs Earnings: Shankar's compensation has been consistent with company performance over the past year.

CEO

Shankar Musunuri (60 yo)

11.3yrs

Tenure

US$4,535,231

Compensation

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. since September 2013 and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Pr...

Leadership Team

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder11.3yrsUS$4.54m0.64%
$ 1.5m
Uday Kompella
Co-founder & Independent Director11.3yrsUS$102.13k0.24%
$ 545.9k
Arun Upadhyay
Chief Scientific Officer and Head of Research & Development2.3yrsUS$1.38m0.037%
$ 84.5k
Ramesh Ramachandran
Principal Financial Officer & Principal Accounting Officerless than a yearno data0.00062%
$ 1.4k
John Kouch
General Counselno datano datano data
Tiffany Hamilton
AVP & Head of Corporate Communicationsno datano datano data
Kristen Craft
Head of People & Cultureless than a yearno datano data
Michael Shine
Senior Vice President of Commercial3.5yrsno datano data
Jyothy Pillai
VP & Head of Regulatory & Quality1.8yrsno datano data
Huma Qamar
Chief Medical Officerless than a yearno data0.00056%
$ 1.3k
Durgaprasad Annavajjula
VP, Head of Program Management & Chief of Staffless than a yearno datano data

1.8yrs

Average Tenure

49yo

Average Age

Experienced Management: OCGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder5.3yrsUS$4.54m0.64%
$ 1.5m
Uday Kompella
Co-founder & Independent Director5.3yrsUS$102.13k0.24%
$ 545.9k
Prabhavathi Fernandes
Lead Independent Director4.7yrsUS$124.63k0.0034%
$ 7.7k
Marna Whittington
Independent Director2.8yrsUS$103.32k0.00034%
$ 766.9
Carl Regillo
Member of Retina Scientific Advisory Board5.1yrsno datano data
David Boyer
Member of Retina Scientific Advisory Boardno datano datano data
Bruce Forrest
Vaccine Scientific Advisory Board Member4yrsno datano data
Junge Zhang
Independent Director5.3yrsUS$87.13k0.40%
$ 902.2k
Geeta Lalwani
Member of Retina Scientific Advisory Boardno datano datano data
Kirsten Castillo
Independent Director4.7yrsUS$110.82k0.026%
$ 58.1k
Satishchandran Chandrasekhar
Vaccine Scientific Advisory Board Member4yrsno datano data
Mark Pennesi
Member of Retina Scientific Advisory Board5.1yrsno datano data

4.9yrs

Average Tenure

60yo

Average Age

Experienced Board: OCGN's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocugen, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Daniil GataulinChardan Capital Markets, LLC
Swayampakula RamakanthH.C. Wainwright & Co.